Background: No standard therapy has been established for localised prostate cancer patients with prostate-specific antigen (PSA) failure after radical prostatectomy (RP).
Objective: To determine whether radiotherapy ± hormone therapy is superior to hormone therapy alone in such patients.
Design, setting, and participants: This study is a multicentre, randomised, open-label, phase 3 trial. Patients with localised prostate cancer whose PSA concentrations had decreased to <0.1 ng/ml after RP, and then increased to 0.4-1.0 ng/ml, were randomised to the salvage hormone therapy (SHT) group (80 mg bicalutamide [BCL] followed by luteinising hormone-releasing hormone agonist in case of BCL failure) or the salvage radiation therapy (SRT) ± SHT group (64.8 Gy of SRT followed by the same regimen as in the SHT group in case of SRT failure). From May 2004 to May 2011, 210 patients (105 in each arm) were registered, with the median follow-up being 5.5 yr.
Outcome measurements and statistical analysis: The primary endpoint was time to treatment failure (TTF) of BCL.
Results and limitations: TTF of BCL was significantly longer in the SRT ± SHT group (8.6 yr) than in the SHT group (5.6 yr; hazard ratio 0.56, 90% confidence interval [0.40-0.77]; one-sided p = 0.001). Thirty-two of 102 patients (31%) in the SRT ± SHT group did not have SRT treatment failure. However, clinical relapse-free survival and overall survival did not differ between the arms. The most frequent grade 3-4 adverse event was erectile dysfunction (83 patients [80%] in the SHT group vs. 76 [74%] in the SRT ± SHT group). Limitations include the short follow-up periods and surrogate endpoint setting to allow definitive conclusions.
Conclusions: Initial SRT prolongs TTF of BCL in patients with post-RP PSA failure, indicating that SRT ± SHT is more beneficial than SHT alone.
Patient summary: Patients who have prostate-specific antigen failure after radical prostatectomy benefit from salvage radiation therapy prior to salvage hormone therapy.
Keywords: Prostate-specific antigen failure; Radical prostatectomy; Salvage therapy.
Copyright © 2019. Published by Elsevier B.V.
Salvage Radiotherapy With or Without Short-Term Hormone Therapy for Rising Prostate-Specific Antigen Concentration After Radical Prostatectomy (GETUG-AFU 16): A Randomised, Multicentre, Open-Label Phase 3 TrialC Carrie et al. Lancet Oncol 17 (6), 747-756. PMID 27160475. - Clinical TrialFrench Ministry of Health, AstraZeneca, and La Ligue Contre le Cancer.
Impact of Early Salvage Radiation Therapy in Patients With Persistently Elevated or Rising Prostate-specific Antigen After Radical ProstatectomyN Fossati et al. Eur Urol 73 (3), 436-444. PMID 28779974.We developed an accurate risk stratification tool to facilitate the individualised recommendation for early SRT based on prostate cancer characteristics. Early SRT proved …
Use of Concomitant Androgen Deprivation Therapy in Patients Treated With Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results From a Large, Multi-institutional SeriesG Gandaglia et al. Eur Urol 73 (4), 512-518. PMID 29229176.The beneficial effect of ADT concomitant to eSRT varied significantly according to disease characteristics, such that only men with more aggressive PCa features benefit f …
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerA Heidenreich et al. Eur Urol 65 (2), 467-79. PMID 24321502. - ReviewThe knowledge in the field of advanced, metastatic, and castration-resistant PCa is rapidly changing. These EAU guidelines on PCa summarise the most recent findings and p …
Use of Androgen Deprivation and Salvage Radiation Therapy for Patients With Prostate Cancer and Biochemical Recurrence After ProstatectomyP Ghadjar et al. Strahlenther Onkol 194 (7), 619-626. PMID 29383406. - ReviewADT combined with SRT appears to improve OS in patients with a PSA level before SRT of ≥0.7 ng/mL. In patients without persistent PSA after prostatectomy and PSA levels o …